Fig. 3. In vivo evaluation of DVP ADCs. Effect of BT474 cell line xenograft in NSG mice (n = 3) up to 60 days post-treatment with (a) C-ADC and (b) NC-ADC. (c) Changes in mouse bodyweight up to 60 days post-treatment with C-ADC or NC-ADC. H&E staining, anti-human IgG (α-hIgG), TUNEL and Ki67 IHC of (d) BT474 and (e) MCF7 mouse xenograft tumours 72 hours post-treatment with C-ADC, NC-ADC, trastuzumab or vehicle (PBS). Quantification of Ki67 levels from IHC analysis of (f) BT474 and (g) MCF7 mouse xenograft tumours (n = 3) 72 hours post-treatment with C-ADC, NC-ADC, trastuzumab or vehicle (PBS). Statistical significance calculated using a two-tailed paired t test by comparison to PBS treated animals. Not significant (ns) p > 0.05, *p < 0.05, **p < 0.005. (h) Pharmacokinetic analysis of the in vivo mouse plasma half-life of NC-ADC and C-ADC.